NO20064049L - Ny assosiasjon mellom agomelatin og et tymoregulerende middel og farmasoytiske sammensetninger inneholdende den - Google Patents

Ny assosiasjon mellom agomelatin og et tymoregulerende middel og farmasoytiske sammensetninger inneholdende den

Info

Publication number
NO20064049L
NO20064049L NO20064049A NO20064049A NO20064049L NO 20064049 L NO20064049 L NO 20064049L NO 20064049 A NO20064049 A NO 20064049A NO 20064049 A NO20064049 A NO 20064049A NO 20064049 L NO20064049 L NO 20064049L
Authority
NO
Norway
Prior art keywords
agomelatine
pharmaceutical compositions
compositions containing
new association
thymoregulatory
Prior art date
Application number
NO20064049A
Other languages
English (en)
Other versions
NO338079B1 (no
Inventor
Christian De Bodinat
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36190792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064049(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20064049L publication Critical patent/NO20064049L/no
Publication of NO338079B1 publication Critical patent/NO338079B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Assosiasjon omfattende agomelatin, eller iV-[2-(7-metoksy-l-naftyl)etyl]acetamid, i assosiasjon med et tymoregulerende middel. Anvendelse av en slik assosiasjon i fremstillingen av medikamenter fior behandling av sinnsstenmingshdelser.
NO20064049A 2005-09-09 2006-09-08 Blanding mellom agomelatin og et tymoregulerende middel til behandling av psykiske lidelser NO338079B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509208A FR2890563B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
NO20064049L true NO20064049L (no) 2007-03-12
NO338079B1 NO338079B1 (no) 2016-07-25

Family

ID=36190792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064049A NO338079B1 (no) 2005-09-09 2006-09-08 Blanding mellom agomelatin og et tymoregulerende middel til behandling av psykiske lidelser

Country Status (38)

Country Link
US (1) US7902180B2 (no)
EP (2) EP2301527A1 (no)
JP (1) JP2007077149A (no)
KR (2) KR20070029607A (no)
CN (1) CN1927194A (no)
AP (1) AP3045A (no)
AR (1) AR055418A1 (no)
AT (1) ATE519482T1 (no)
AU (1) AU2006209371B2 (no)
BR (1) BRPI0603767A (no)
CA (1) CA2558764C (no)
CY (1) CY1112223T1 (no)
DK (1) DK1762238T3 (no)
EA (1) EA014381B1 (no)
ES (1) ES2371482T3 (no)
FR (1) FR2890563B1 (no)
GE (1) GEP20094741B (no)
GT (1) GT200600410A (no)
HR (1) HRP20110749T1 (no)
JO (1) JO2746B1 (no)
MA (1) MA28504B1 (no)
ME (1) ME01964B (no)
MX (1) MXPA06010234A (no)
MY (1) MY162318A (no)
NO (1) NO338079B1 (no)
NZ (1) NZ549727A (no)
PE (1) PE20070613A1 (no)
PL (1) PL1762238T3 (no)
PT (1) PT1762238E (no)
RS (1) RS52003B (no)
SA (1) SA110320045B1 (no)
SG (1) SG131029A1 (no)
SI (1) SI1762238T1 (no)
TW (1) TWI369980B (no)
UA (1) UA83541C2 (no)
UY (1) UY29776A1 (no)
WO (1) WO2007028903A1 (no)
ZA (1) ZA200607532B (no)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP1185259A1 (en) * 1999-04-29 2002-03-13 MERCK PATENT GmbH Glycine cleavage system inhibitors as potential antipsychotics
AR026610A1 (es) * 1999-12-01 2003-02-19 Ucb Sa Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Also Published As

Publication number Publication date
AU2006209371B2 (en) 2012-02-02
AR055418A1 (es) 2007-08-22
US7902180B2 (en) 2011-03-08
KR20090056949A (ko) 2009-06-03
SI1762238T1 (sl) 2011-10-28
AP3045A (en) 2014-11-30
PL1762238T3 (pl) 2011-12-30
EP1762238B1 (fr) 2011-08-10
JO2746B1 (en) 2014-03-15
US20070066689A1 (en) 2007-03-22
ATE519482T1 (de) 2011-08-15
MA28504B1 (fr) 2007-04-03
NO338079B1 (no) 2016-07-25
SA110320045B1 (ar) 2014-01-29
MY162318A (en) 2017-05-31
EP2301527A1 (fr) 2011-03-30
FR2890563B1 (fr) 2007-10-19
GT200600410A (es) 2007-05-21
EP1762238A1 (fr) 2007-03-14
UY29776A1 (es) 2006-11-30
SG131029A1 (en) 2007-04-26
TWI369980B (en) 2012-08-11
AP2008004380A0 (en) 2008-04-30
CA2558764A1 (fr) 2007-03-09
WO2007028903A1 (fr) 2007-03-15
FR2890563A1 (fr) 2007-03-16
DK1762238T3 (da) 2011-11-07
ES2371482T3 (es) 2012-01-03
AU2006209371A1 (en) 2007-03-29
PT1762238E (pt) 2011-09-01
JP2007077149A (ja) 2007-03-29
GEP20094741B (en) 2009-07-27
BRPI0603767A (pt) 2007-08-14
EA014381B1 (ru) 2010-10-29
CA2558764C (fr) 2013-01-08
HRP20110749T1 (hr) 2011-11-30
KR20070029607A (ko) 2007-03-14
UA83541C2 (uk) 2008-07-25
TW200800860A (en) 2008-01-01
CY1112223T1 (el) 2015-12-09
MXPA06010234A (es) 2007-03-08
PE20070613A1 (es) 2007-07-30
ZA200607532B (en) 2008-05-28
NZ549727A (en) 2008-03-28
ME01964B (me) 2012-04-30
CN1927194A (zh) 2007-03-14
EA200601450A1 (ru) 2007-04-27
RS52003B (sr) 2012-04-30

Similar Documents

Publication Publication Date Title
EA200700574A3 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения генерализированного тревожного расстройства
WO2005079851A3 (en) Dopamine-agonist combination therapy with sedatives for improving sleep quality
EA200500399A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
ATE549323T1 (de) Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
EA200702318A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса
TNSN07364A1 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
NO20064049L (no) Ny assosiasjon mellom agomelatin og et tymoregulerende middel og farmasoytiske sammensetninger inneholdende den
NO20064048L (no) Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den
NO20076002L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi
DK1567140T3 (da) Synergistisk kombination der omfatter roflumilast og (R,R)-formoterol
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
AR025498A1 (es) Una nueva asociacion farmaceutica que presenta un efecto analgesico

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees